Bal Pharma Limited

NSEI:BALPHARMA Stock Report

Market Cap: ₹1.6b

Bal Pharma Management

Management criteria checks 3/4

Bal Pharma's CEO is Shailesh Siroya, appointed in Jan 2019, has a tenure of 5.33 years. total yearly compensation is ₹12.24M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 19.41% of the company’s shares, worth ₹305.46M. The average tenure of the management team and the board of directors is 3.7 years and 4 years respectively.

Key information

Shailesh Siroya

Chief executive officer

₹12.2m

Total compensation

CEO salary percentage100.0%
CEO tenure5.3yrs
CEO ownership19.4%
Management average tenure3.7yrs
Board average tenure4yrs

Recent management updates

Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Sep 18
Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?

Mar 14
Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?

Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up

Feb 01
Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up

Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Sep 18
Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00

Aug 28
Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Aug 14
Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Aug 17
Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00

Jul 31
Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00

Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?

Mar 08
Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?

Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky

Nov 23
Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky

Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?

Aug 10
Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?

Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?

Aug 10
Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?

CEO Compensation Analysis

How has Shailesh Siroya's remuneration changed compared to Bal Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

₹35m

Sep 30 2023n/an/a

₹32m

Jun 30 2023n/an/a

₹24m

Mar 31 2023₹12m₹12m

₹26m

Dec 31 2022n/an/a

₹29m

Jun 30 2022n/an/a

₹43m

Mar 31 2022₹10m₹10m

₹56m

Dec 31 2021n/an/a

₹72m

Jun 30 2021n/an/a

₹59m

Mar 31 2021₹10m₹10m

₹47m

Dec 31 2020n/an/a

-₹34m

Sep 30 2020n/an/a

-₹73m

Jun 30 2020n/an/a

-₹95m

Mar 31 2020₹10m₹10m

-₹122m

Dec 31 2019n/an/a

-₹52m

Sep 30 2019n/an/a

-₹15m

Jun 30 2019n/an/a

-₹21m

Mar 31 2019₹8m₹8m

₹38m

Dec 31 2018n/an/a

₹29m

Mar 31 2018₹8m₹8m

₹28m

Compensation vs Market: Shailesh's total compensation ($USD146.72K) is above average for companies of similar size in the Indian market ($USD39.29K).

Compensation vs Earnings: Shailesh's compensation has been consistent with company performance over the past year.

CEO

Shailesh Siroya (57 yo)

5.3yrs

Tenure

₹12,240,000

Compensation

Mr. Shailesh Dheerajmal Siroya serves as the Managing Director of BAL Pharma Limited. Mr. Siroya served as the Managing Director of BAL Pharma Limited since August 1, 1994. With rich experience, Mr. Siroya...

Leadership Team

NamePositionTenureCompensationOwnership
Shailesh Siroya
MD & Executive Director5.3yrs₹12.24m19.41%
₹ 305.5m
Daddanala Bharath Bhushan
Chief Financial Officerno data₹365.00kno data
Himesh Virupakshaya
Whole Time Director3.7yrs₹3.32mno data
Ravindra Kothari
Deputy General Manager of Internal Auditno datano datano data
Abdul Basith
Company Secretary & Compliance Officerless than a yearno datano data
D. Bhat
Assistant Vice President of Sales & Marketingno datano datano data
Archana Mitra
Vice President of International Marketing & HRno data₹534.34kno data

3.7yrs

Average Tenure

60yo

Average Age

Experienced Management: BALPHARMA's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Shailesh Siroya
MD & Executive Director26.7yrs₹12.24m19.41%
₹ 305.5m
Himesh Virupakshaya
Whole Time Director4.7yrs₹3.32mno data
Champion Irohailsrinivas
Non-Executive Independent Director4.9yrs₹38.00kno data
Nicola Neeladrie
Independent Non-Executive Director4yrs₹49.00kno data
H. Venkatesh
Non-Executive Additional Independent Director4yrs₹32.00kno data
Jatish Sheth
Additional Non-Executive Director3.4yrs₹46.00kno data
Kotian Damodar
Additional Non-Independent Director2yrs₹1.87mno data

4.0yrs

Average Tenure

59.5yo

Average Age

Experienced Board: BALPHARMA's board of directors are considered experienced (4 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.